NO20030231L - Proteinkompleks som fungerer som en vehikkel for oralt administrerbare medikamenter - Google Patents
Proteinkompleks som fungerer som en vehikkel for oralt administrerbare medikamenterInfo
- Publication number
- NO20030231L NO20030231L NO20030231A NO20030231A NO20030231L NO 20030231 L NO20030231 L NO 20030231L NO 20030231 A NO20030231 A NO 20030231A NO 20030231 A NO20030231 A NO 20030231A NO 20030231 L NO20030231 L NO 20030231L
- Authority
- NO
- Norway
- Prior art keywords
- protein complex
- acts
- vehicle
- orally administered
- administered drugs
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 241000193155 Clostridium botulinum Species 0.000 abstract 1
- 230000000536 complexating effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10035156A DE10035156A1 (de) | 2000-07-19 | 2000-07-19 | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
| DE10035155 | 2000-07-19 | ||
| PCT/DE2001/002816 WO2002005844A2 (de) | 2000-07-19 | 2001-07-19 | Proteinkomplex als vehikel für oral verfügbare arzneimittel |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20030231D0 NO20030231D0 (no) | 2003-01-17 |
| NO20030231L true NO20030231L (no) | 2003-03-18 |
Family
ID=26006444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20030231A NO20030231L (no) | 2000-07-19 | 2003-01-17 | Proteinkompleks som fungerer som en vehikkel for oralt administrerbare medikamenter |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20040028703A1 (xx) |
| EP (1) | EP1303535A2 (xx) |
| JP (1) | JP2004503600A (xx) |
| KR (1) | KR100822006B1 (xx) |
| CN (1) | CN100497379C (xx) |
| AU (2) | AU2001285688B2 (xx) |
| BR (1) | BR0112515A (xx) |
| CA (1) | CA2415712A1 (xx) |
| CU (1) | CU23381A3 (xx) |
| CZ (1) | CZ2003169A3 (xx) |
| DE (2) | DE10035156A1 (xx) |
| HU (1) | HUP0301644A3 (xx) |
| IL (1) | IL153539A0 (xx) |
| MX (1) | MXPA03000566A (xx) |
| NO (1) | NO20030231L (xx) |
| PL (1) | PL364993A1 (xx) |
| RU (1) | RU2002134755A (xx) |
| WO (1) | WO2002005844A2 (xx) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| JP2003009897A (ja) * | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
| JP2007070225A (ja) * | 2003-07-25 | 2007-03-22 | Yukako Fujinaga | クロストリジウム属菌由来成分を含む医薬製剤 |
| DE102004035606A1 (de) * | 2004-07-22 | 2006-03-30 | Biotecon Therapeutics Gmbh | Carrier für Arzneimittel zur Gewinnung der oralen Bioverfügbarkeit |
| CA2576971A1 (en) * | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| JP2009081997A (ja) * | 2007-09-27 | 2009-04-23 | Chemo Sero Therapeut Res Inst | ボツリヌス毒素成分ｈａを核酸の細胞内導入キャリアーとして利用する方法 |
| WO2009131435A1 (en) * | 2008-04-23 | 2009-10-29 | Erasmus University Medical Center Rotterdam | Linker containing bungarotoxin and a binding peptide |
| CA2745657C (en) | 2008-12-04 | 2022-06-21 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
| US20130085267A1 (en) * | 2009-12-18 | 2013-04-04 | Allergan, Inc. | Stabilization of Therapeutic Agents to Facilitate Administration |
| KR101134146B1 (ko) * | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US11096993B2 (en) | 2016-12-08 | 2021-08-24 | Gary E. Borodic | Method of treating macular degeneration using botulinum toxin-based pharmaceuticals |
| US11123411B2 (en) * | 2016-12-08 | 2021-09-21 | Gary E. Borodic | Method of treating macular degeneration using botulinum toxin-based pharmaceuticals |
| US20210121542A1 (en) * | 2019-10-28 | 2021-04-29 | Prime Bio, Inc. | Composition for delivery of protein therapeutics through oral, sublingual and buccal route |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ286242A (en) * | 1991-03-26 | 1997-11-24 | Csl Ltd | Use of veterinary implant as a single dose vaccination system: rupturable polymer film coating around core of active agent and water soluble excipient |
| GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
| AU4646393A (en) * | 1992-06-23 | 1994-01-24 | Interactive Biologics Associates | Pharmaceutical composition containing botulinum b complex |
| JP4129544B2 (ja) * | 1993-03-29 | 2008-08-06 | ファイザー・インク | サポニンアジュバント使用の多成分系クロストリジウム・ワクチン |
| US5562907A (en) * | 1993-05-14 | 1996-10-08 | Arnon; Stephen S. | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins |
| EP0702559B1 (en) * | 1993-06-10 | 2003-03-19 | Allergan, Inc. | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
| JP3523879B2 (ja) * | 1994-05-31 | 2004-04-26 | アレルガン インコーポレイテッド | 輸送タンパク質用クロストリジウム属細菌毒素の修飾 |
| US6004583A (en) * | 1995-03-22 | 1999-12-21 | Orex Pharmaceutical Development Corp. | Protein-containing polymer composition for oral administration |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US6699966B1 (en) * | 1996-07-08 | 2004-03-02 | University Of Massachusetts | Proteins within the type E botulinum neurotoxin complex |
| DE19735105A1 (de) * | 1997-08-13 | 1999-03-04 | Univ Albert Ludwigs Freiburg | Transportsystem zur Einbringung von Proteinen in Zielzellen mit Hilfe eines Fusionsproteins, Nucleinsäurekonstrukte kodierend für die Komponenten des Transportsystems und Arzneimittel, die Komponenten des Transportsystems umfassen |
| US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
| WO1999037326A1 (en) * | 1998-01-26 | 1999-07-29 | University Of Massachusetts | Biologically active hemagglutinin from type a clostridium botulinum and methods of use |
| US5955368A (en) * | 1998-04-06 | 1999-09-21 | Wisconsin Alumni Research Foundation | Expression system for clostridium species |
| DE19856897A1 (de) * | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
| US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| DK1514556T3 (da) * | 2000-02-08 | 2011-10-24 | Allergan Inc | Farmaceutiske sammensætninger med botulinustoxin |
| JP2003009897A (ja) * | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| JP2005538954A (ja) * | 2002-05-31 | 2005-12-22 | トーマス・ジェファーソン・ユニバーシティ | 分子の経上皮輸送用組成物及び方法 |
| US20050169942A1 (en) * | 2003-10-07 | 2005-08-04 | Allergan, Inc. | Novel DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain for production of therapeutics |
| US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| US7514088B2 (en) * | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
| US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
| WO2006101809A1 (en) * | 2005-03-15 | 2006-09-28 | Allergan, Inc. | Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| FR2896693B1 (fr) * | 2006-01-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition comprenant plusieurs toxines botuliques |
-
2000
- 2000-07-19 DE DE10035156A patent/DE10035156A1/de not_active Withdrawn
-
2001
- 2001-07-19 BR BR0112515-0A patent/BR0112515A/pt not_active IP Right Cessation
- 2001-07-19 PL PL01364993A patent/PL364993A1/xx not_active Application Discontinuation
- 2001-07-19 RU RU2002134755/13A patent/RU2002134755A/ru not_active Application Discontinuation
- 2001-07-19 AU AU2001285688A patent/AU2001285688B2/en not_active Ceased
- 2001-07-19 JP JP2002511776A patent/JP2004503600A/ja active Pending
- 2001-07-19 HU HU0301644A patent/HUP0301644A3/hu unknown
- 2001-07-19 IL IL15353901A patent/IL153539A0/xx unknown
- 2001-07-19 US US10/333,477 patent/US20040028703A1/en not_active Abandoned
- 2001-07-19 EP EP01964858A patent/EP1303535A2/de not_active Withdrawn
- 2001-07-19 CA CA002415712A patent/CA2415712A1/en not_active Abandoned
- 2001-07-19 DE DE10192679T patent/DE10192679D2/de not_active Expired - Fee Related
- 2001-07-19 WO PCT/DE2001/002816 patent/WO2002005844A2/de active IP Right Grant
- 2001-07-19 CN CNB018130909A patent/CN100497379C/zh not_active Expired - Fee Related
- 2001-07-19 AU AU8568801A patent/AU8568801A/xx active Pending
- 2001-07-19 MX MXPA03000566A patent/MXPA03000566A/es not_active Application Discontinuation
- 2001-07-19 KR KR1020037000614A patent/KR100822006B1/ko not_active IP Right Cessation
- 2001-07-19 CZ CZ2003169A patent/CZ2003169A3/cs unknown
-
2003
- 2003-01-10 CU CU20030009A patent/CU23381A3/es not_active IP Right Cessation
- 2003-01-17 NO NO20030231A patent/NO20030231L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CU23381A3 (es) | 2009-06-25 |
| US20040028703A1 (en) | 2004-02-12 |
| JP2004503600A (ja) | 2004-02-05 |
| CN1443196A (zh) | 2003-09-17 |
| AU8568801A (en) | 2002-01-30 |
| MXPA03000566A (es) | 2004-12-13 |
| WO2002005844A2 (de) | 2002-01-24 |
| NO20030231D0 (no) | 2003-01-17 |
| RU2002134755A (ru) | 2004-07-10 |
| BR0112515A (pt) | 2003-07-01 |
| CZ2003169A3 (cs) | 2004-02-18 |
| DE10192679D2 (de) | 2003-06-18 |
| DE10035156A1 (de) | 2002-02-07 |
| WO2002005844A8 (de) | 2002-02-14 |
| CN100497379C (zh) | 2009-06-10 |
| HUP0301644A3 (en) | 2010-01-28 |
| IL153539A0 (en) | 2003-07-06 |
| EP1303535A2 (de) | 2003-04-23 |
| AU2001285688B2 (en) | 2005-09-08 |
| HUP0301644A2 (hu) | 2003-08-28 |
| KR100822006B1 (ko) | 2008-04-15 |
| KR20030045013A (ko) | 2003-06-09 |
| PL364993A1 (en) | 2004-12-27 |
| WO2002005844A3 (de) | 2002-06-27 |
| CA2415712A1 (en) | 2003-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20030231L (no) | Proteinkompleks som fungerer som en vehikkel for oralt administrerbare medikamenter | |
| TR200201082T2 (tr) | Glikopriranoziloksipirazol türevleri | |
| TR200200768T2 (tr) | Yeni kuinüklidin türevleri ve bunu içeren ilaç bileşimleri | |
| CY1108007T1 (el) | Φαρμακευτικες συνθεσεις βοτουλινικης τοξινης | |
| SE0003449L (sv) | Cancerhämmande kompositioner | |
| TR200102928T2 (tr) | Farmasötik bileşikler. | |
| NO20014035L (no) | System for oral administrasjon av medikament | |
| DE69636531D1 (de) | Verfahren, zusammensetzungen und kits zur erhöhung der oralen bioverfügbarkeit von pharmazeutika | |
| NO20035763L (no) | Tetrahydrokinolinderivater, farmasøytiske preparater omfattende slike samt anvendelse av slike for fremstilling av medikament for kontroll av fruktbarhet. | |
| DK0994710T3 (da) | Farmaceutiske præparater til oral indgivelse omfattende en benzhydrylpiperazin og en cyclodextrin | |
| HUP0203437A2 (en) | Use of resorcinol derivatives for producing pharmaceutical compositions for treatment of immune diseases | |
| ATE353013T1 (de) | Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel | |
| DE60019167D1 (de) | Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason | |
| HUP9900346A2 (hu) | Avermektineket és depszipeptideket tartalmazó endoparazita ellenes hatású gyógyászati készítmények | |
| DE60031504D1 (de) | Fluticasonpropionat arzneizubereitung | |
| FR2764889B1 (fr) | Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant | |
| NO20050066L (no) | Pegylert T20 polypeptid | |
| NO990789D0 (no) | Cytotoksisk aminosukker og beslektede sukker-derivater av indolopyrrolokarbazoler | |
| DE69938935D1 (de) | Zyklische conotoxin-peptide | |
| TR199801861T2 (xx) | Farmas�tik olarak yararl� bile�imler. | |
| DK1079849T3 (da) | Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning | |
| IT1314185B1 (it) | Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi | |
| HUP0200055A2 (hu) | 16-Hidroxi-ösztratriének és ezeket tartalmazó gyógyszerkészítmények | |
| ATE477271T1 (de) | Niedermolekulare peptide als inhibitoren der laminin/nidogen wechselwirkung | |
| EP1273301A3 (en) | Pharmaceutical preparations based on active ingredients susceptible to illict administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |